SDB-005

SDB-005 is an indazole-based synthetic cannabinoid that has been sold online as a designer drug.[1] It is presumed to be an agonist of the CB₁ and CB₂ cannabinoid receptors. SDB-005 is the indazole core analog of PB-22 where the 8-hydroxyquinoline has also been replaced with a naphthalene group.

SDB-005

Legal status
Legal status	CA: Schedule II DE: NpSG (Industrial and scientific use only) UK: Class B
Identifiers
IUPAC name Naphthalen-1-yl 1-pentyl-1H-indazole-3-carboxylate
ChemSpider	30922481
Chemical and physical data
Formula	C23H22N2O2
Molar mass	358.441 g·mol^−1
3D model (JSmol)	Interactive image
SMILES CCCCCN1N=C(C(=O)OC2=CC=CC3=C2C=CC=C3)C2=C1C=CC=C2
InChI InChI=1S/C23H22N2O2/c1-2-3-8-16-25-20-14-7-6-13-19(20)22(24-25)23(26)27-21-15-9-11-17-10-4-5-12-18(17)21/h4-7,9-15H,2-3,8,16H2,1H3 Key:JBVNFKZVDLFOAY-UHFFFAOYSA-N

The code number SDB-005 was originally used for a different compound, the N-phenyl instead of N-benzyl analogue of SDB-006. This compound is a potent agonist of the CB₁ receptor (K_i = 21 nM) and CB₂ receptor (K_i = 140 nM).[2]

Original, non designer drug SDB-005

However, SDB-005 was subsequently used as the name for the indazole-3-carboxylate compound mentioned above when it was sold in Europe as a designer drug, and was entered into the EMCDDA synthetic drug database under this name.[3] Consequently, there are now two distinct, yet fairly closely related cannabinoid compounds, which may both be referred to under the code SDB-005.

See also

• 5F-PB-22
• AM-2201
• BB-22
• JWH-018
• NM-2201
• NNE1

References

1. "SDB-005". Cayman Chemical. Retrieved 27 June 2015.
2. Banister SD, Wilkinson SM, Longworth M, Stuart J, Apetz N, English K, et al. (July 2013). "The synthesis and pharmacological evaluation of adamantane-derived indoles: cannabimimetic drugs of abuse". ACS Chemical Neuroscience. 4 (7): 1081–92. doi:10.1021/cn400035r. PMC 3715837. PMID 23551277.
3. EWS_EU: Neue Psychoaktive Substanzen, April 2015